Yes, dapagliflozin should be continued long-term after MI in hemodynamically stable post-PCI patients
Dapagliflozin 10 mg once daily is recommended for long-term use after myocardial infarction in hemodynamically stable patients post-PCI, particularly when diabetes, heart failure, or chronic kidney disease are present. The FDA-approved indications explicitly support chronic use to reduce cardiovascular death and heart failure hospitalization 1.
Evidence-Based Rationale
FDA-Approved Indications Support Long-Term Use
The FDA label for dapagliflozin specifies 10 mg once daily for:
- Reducing risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in patients with heart failure 1
- Reducing risk of heart failure hospitalization in type 2 diabetes patients with established cardiovascular disease or multiple CV risk factors 1
- Reducing risk of sustained eGFR decline, ESKD, CV death, and heart failure hospitalization in chronic kidney disease patients 1
These are chronic indications without specified duration limits, distinguishing dapagliflozin from time-limited post-MI therapies like dual antiplatelet therapy.
Recent High-Quality Trial Evidence
The DAPA-MI trial (2024) 2 enrolled 4,017 post-MI patients without prior diabetes or heart failure and demonstrated that dapagliflozin significantly improved cardiometabolic outcomes (win ratio 1.34,95% CI 1.20-1.50, p<0.001) over approximately 1 year. While the composite of CV death/heart failure hospitalization showed no significant difference in this lower-risk population, the trial established safety and cardiometabolic benefits with continued use 2.
In diabetic post-MI patients specifically, a 2026 randomized trial 3 showed dapagliflozin dramatically reduced heart failure events at 18 months (5.3% vs 29.5%, HR 0.18, p<0.001) and improved LVEF by 1.56% compared to placebo. This demonstrates sustained benefit with continued therapy.
Comparison to Established Post-MI Therapies
Unlike antiplatelet therapy which has defined durations (1-12 months for DAPT depending on stent type and bleeding risk 4, 5), dapagliflozin follows the model of other indefinite post-MI medications:
- ACE inhibitors: "Continue indefinitely in all patients with LV dysfunction or symptoms of heart failure" 4
- Beta-blockers: "Continue indefinitely in patients with STEMI" 4
- Aspirin: "Should be continued indefinitely" 4
The 2024 ESC guidelines 6 and 2020 ESC diabetes guidelines 7 recommend SGLT2 inhibitors (including dapagliflozin) for patients with diabetes and CVD "to reduce CV events" without specifying discontinuation, supporting indefinite use.
Clinical Decision Algorithm
Continue dapagliflozin long-term if:
- Patient has diabetes, heart failure (any EF), or CKD (eGFR ≥25 mL/min/1.73 m²) 1
- Hemodynamically stable (no hypotension, shock, or volume depletion) 1
- No contraindications (eGFR <25 at initiation, history of serious hypersensitivity) 1
Monitor during long-term therapy:
- Renal function periodically (expect initial 3-6 mL/min/1.73 m² eGFR dip from tubuloglomerular feedback—this is not nephrotoxicity) 8
- Volume status, especially if on concurrent diuretics
- Continue even if eGFR falls below 25 during treatment (do not discontinue) 1
Important Caveats
Temporary interruption required: Withhold dapagliflozin for at least 3 days before major surgery or procedures with prolonged fasting; resume when clinically stable and oral intake restored 1. This is the only planned interruption in long-term therapy.
Ketoacidosis monitoring: While rare in type 2 diabetes, assess for ketoacidosis if patients present with nausea, vomiting, abdominal pain, or shortness of breath, even with normal glucose levels 1. This risk does not preclude long-term use but requires awareness.
Renal function thresholds differ by indication:
- For glycemic control in diabetes: not recommended if eGFR <45 mL/min/1.73 m² 1
- For heart failure/CKD/CV risk reduction: can continue down to eGFR 25 mL/min/1.73 m² 1
The evidence strongly supports that dapagliflozin is not a short-term post-MI medication but rather a chronic cardiovascular and cardiometabolic therapy that should be maintained indefinitely in appropriate patients, similar to statins, ACE inhibitors, and beta-blockers.